Pemphigus during the COVID-19 Epidemic: Infection Risk, Vaccine Responses and Management Strategies.

Area of Science:

• Immunology
• Dermatology
• Infectious Diseases

Background:

• Pemphigus is a severe autoimmune blistering disease requiring immunosuppression.
• The COVID-19 pandemic presents unique challenges for immunocompromised patients.
• COVID-19 vaccines are crucial for protection, but concerns exist regarding autoimmune conditions.

Purpose of the Study:

• To review the interplay between COVID-19 vaccination and pemphigus.
• To explore management strategies for pemphigus patients during the pandemic.
• To assess the risk-benefit profile of COVID-19 vaccination in pemphigus patients.

Main Methods:

• Literature review of studies on COVID-19 and pemphigus.
• Analysis of reported cases of pemphigus onset or flares post-vaccination.
• Discussion of current treatment guidelines and future research directions.

Main Results:

• COVID-19 vaccination generally shows a favorable risk-benefit profile for pemphigus patients.
• While rare, new pemphigus onset or flares have been reported post-vaccination.
• Pemphigus patients may not be at higher risk for COVID-19 infection compared to the general population.

Conclusions:

• Clinicians should encourage COVID-19 vaccination for pemphigus patients after careful assessment.
• Interrupting immunosuppressive therapy for pemphigus can lead to adverse outcomes.
• Further research is needed to clarify the definitive association between COVID-19 vaccination and pemphigus.